| Laurie Tarumoto-young, OD | |
|
480 Central Ave, Jbphh, HI 96860-4908 | |
| (808) 257-3365 | |
| Not Available |
| Full Name | Laurie Tarumoto-young |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 480 Central Ave, Jbphh, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063401487 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OD248 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Laurie Tarumoto-young, OD 480 Central Ave, Jbphh, HI 96860-4908 Ph: () - | Laurie Tarumoto-young, OD 480 Central Ave, Jbphh, HI 96860-4908 Ph: (808) 257-3365 |
News Archive
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.
Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.
Infant formula and other baby foods that provide permanent protection from obesity and diabetes into adulthood could be on shop shelves soon, reports Lisa Melton in Chemistry & Industry, the magazine of the SCI.
Hematology researchers have used a single injection of gene therapy to correct a rare bleeding disorder, factor VII deficiency, in dogs. This success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.
› Verified 2 days ago
Dr. Bryan Wade Sixkiller, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 15th Medical Group, 755 Scott Circle, Jbphh, HI 96853 Phone: 808-448-6160 |